Amended Statement of Ownership (sc 13g/a)
15 2월 2022 - 8:22AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
SCHEDULE
13G
Under
the Securities Exchange Act of 1934
(Amendment
No. 3)
OVID
THERAPEUTICS INC.
(Name
of Issuer)
COMMON
STOCK, $0.001 PAR VALUE
(Title
of Class of Securities)
690469101
(CUSIP
Number)
DECEMBER
31, 2021
(Date
of Event Which Requires Filing of This Statement)
Check
the appropriate box to designate the rule pursuant to which this Schedule is filed:
☐
Rule 13d-1(b)
☐
Rule 13d-1(c)
☒
Rule 13d-1(d)
|
*
|
The
remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject
class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior
cover page.
|
The information
required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities
Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all
other provisions of the Act (however, see the Notes).
|
|
|
|
|
|
|
CUSIP
No. 690469101
|
|
Page
2 of 5 Pages
|
|
|
|
|
|
|
|
|
|
1.
|
|
Name of Reporting
Persons
Matthew
During
|
|
2.
|
|
Check the
Appropriate Box if a Member of a Group (See Instructions)
(a) ☐
(b) ☒
|
|
3.
|
|
SEC
USE ONLY
|
|
4.
|
|
Citizenship
or Place of Organization
United
States of America
|
|
|
|
|
|
|
|
|
|
Number
of
Shares
Beneficially
Owned
by
Each
Reporting
Person
With:
|
|
5.
|
|
Sole Voting
Power
3,103,932
(1)
|
|
|
6.
|
|
Shared Voting
Power
0
|
|
|
7.
|
|
Sole Dispositive
Power
3,103,932
(1)
|
|
|
8.
|
|
Shared Dispositive
Power
0
|
|
|
|
|
|
|
|
|
|
9.
|
|
Aggregate
Amount Beneficially Owned by Each Reporting Person
3,103,932
(1)
|
|
10.
|
|
Check if
the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
☐
|
|
11.
|
|
Percent of
Class Represented by Amount in Row (9)
4.5%(2)
|
|
12.
|
|
Type of Reporting
Person (See Instructions)
IN
|
|
(1)
|
Consists
of (i) 2,357,727 shares of the Issuer’s common stock held directly by the Reporting Person and (ii) 746,205 shares of common
stock issuable upon the exercise of stock options within 60 days of December 31, 2021.
|
|
(2)
|
This
percentage is calculated based upon 68,092,185 outstanding shares of the Issuer’s common stock, as reported in the Issuer’s
Form 10-Q Quarterly Report (Commission File No. 001-38085) filed with the Securities and Exchange Commission on November 10, 2021.
|
|
CUSIP
No. 690469101
|
|
Page
3 of 5 Pages
|
Ovid Therapeutics
Inc.
|
Item
1(b)
|
Address
of Issuer’s Principal Executive Offices
|
1460 Broadway,
Suite 15044
New York, New
York 10036
Item
2(a) Name of Person Filing
Matthew
During
|
Item
2(b)
|
Address
of Principal Business Office or, if none, Residence
|
c/o Ovid
Therapeutics Inc.
1460 Broadway,
Suite 15044
New York, New
York 10036
United
States of America
|
Item
2(d)
|
Title
of Class of Securities
|
Common
Stock, $0.001 par value
690469101
Not applicable.
Provide
the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1
(a) Amount
beneficially owned: See Row 9 of cover page for each Reporting Person
(b) Percent
of class: See Row 11 of cover page for each Reporting Person
(c) Number
of shares as to which the person has:
(i) Sole power
to vote or to direct the vote: See Row 5 of cover page for each Reporting Person.
(ii) Shared power
to vote or to direct the vote: See Row 6 of cover page for each Reporting Person.
(iii) Sole power
to dispose or to direct the disposition of: See Row 7 of cover page for each Reporting Person.
(iv) Shared power
to dispose or to direct the disposition of: See Row 8 of cover page for each Reporting Person.
|
Item
5
|
Ownership
of Five Percent or Less of a Class
|
If this
statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of
more than five percent of the class of securities, check the following. ☒
|
Item
6
|
Ownership
of More than Five Percent of Another Person
|
Not applicable.
|
CUSIP
No. 690469101
|
|
Page
4 of 5 Pages
|
|
Item
7
|
Identification
and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company
|
Not applicable.
|
Item
8
|
Identification
and Classification of Members of the Group
|
Not applicable.
|
Item
9
|
Notice
of Dissolution of Group
|
Not applicable.
Not applicable.
|
CUSIP
No. 690469101
|
|
Page
5 of 5 Pages
|
SIGNATURE
After
reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete
and correct.
Dated:
February 14, 2022.
|
|
|
|
|
|
|
By:
|
|
/s/
Matthew During
|
|
|
|
|
Matthew
During
|
Ovid Therapeutics (NASDAQ:OVID)
과거 데이터 주식 차트
부터 1월(1) 2025 으로 2월(2) 2025
Ovid Therapeutics (NASDAQ:OVID)
과거 데이터 주식 차트
부터 2월(2) 2024 으로 2월(2) 2025
